

EURICAN DAP LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION

Authorised

- Canine adenovirus 2, strain DK13, Live
- Canine distemper virus, strain BA5, Live
- Canine parvovirus, strain CAG2, Live

Product identification

Medicine name:

EURICAN DAP LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION

Active substance:

Canine adenovirus 2, strain DK13, Live
Canine distemper virus, strain BA5, Live
Canine parvovirus, strain CAG2, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine adenovirus 2, strain DK13, Live
2.50 log₁₀ 50% cell culture infectious dose / 1.00 Dose
Canine distemper virus, strain BA5, Live
4.00 log₁₀ 50% cell culture infectious dose / 1.00 Dose
Canine parvovirus, strain CAG2, Live
4.90 log₁₀ 50% cell culture infectious dose / 1.00 Dose

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AD02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Netherlands

Available in:

Netherlands

Package description:

Plastic box of 10 vials of lyophilisate (1 dose) and 10 vials of solvent (1 ml)
Plastic box of 50 vials of lyophilisate (1 dose) and 50 vials of solvent (1 ml)
Plastic box of 10 vials of lyophilisate (1 dose)
Plastic box of 50 vials of lyophilisate (1 dose)
Plastic box of 10 vials of solvent (1 ml)
Plastic box of 50 vials of solvent (1 ml)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Boehringer Ingelheim Animal Health Netherlands B.V.

Marketing authorisation date:

12/08/2017

Manufacturing sites for batch release:

Boehringer Ingelheim Animal Health France

Responsible authority:

Medicines Evaluation Board

Authorisation number:

REG NL 118422

Date of authorisation status change:

26/08/2022

Reference member state:

France

Procedure number:

FR/V/0305/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland
Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Malta
Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain
Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 13/03/2026

[Download](#)

eu-puar-frv0305001-mr-rpe791-en.pdf